Ofatumumab for relapsing forms of multiple sclerosis.
Sign Up to like & getrecommendations! Published in 2022 at "Drugs of today"
DOI: 10.1358/dot.2022.58.1.3353168
Abstract: In recent years, B cells have been extensively studied as a therapeutic target in multiple sclerosis (MS). Particularly, anti-CD20 monoclonal antibodies (MAbs) such as rituximab or ocrelizumab have proven to be effective in treating various… read more here.
Keywords: relapsing forms; anti cd20; forms multiple; ofatumumab relapsing ... See more keywords